drugset / Trial / NCT02809105

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

NCT02809105

Phase 3 Completed 186 enrolled Astellas Pharma Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to verify the efficacy and investigate the safety of the study drug when ASP0456 is administered orally for 4 weeks and 52 weeks.

Timeline

Start
2016-06-24
Primary completion
2016-11-14
Completion
2017-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide Oral

Indications